Redefining market access success with Reimbursography – June 5, 2015

There’s no better feeling when running a strategic health + wellness communications agency than to identify a need, and be able to deliver a solution. We get to do that today with the introduction of Reimbursography – a strategic communications programme that leverages country-specific access insights to shape the value context for reimbursement success. Reimbursography…

Read More

PBAC advises biosimilar medicines suitable for substitution at pharmacy level – June 2, 2015

In late April, 2015, The Pharmaceutical Benefits Advisory Committee (PBAC) pledged to consider marking biosimilar medicines equivalent to originator medicines, to which they are referenced against in Australia. This process would involve “a flagging”, whereby the biosimilar would be compared to the originator, in order to identify any significant differences in clinical efficacy or safety.…

Read More

7.9 month improvement in metastatic bowel cancer patients following microsphere radiotherapy and chemotherapy – June 2, 2015

As published on Bowel Cancer Australia’s website today, results from an Australian-led global study have shown that treatment with radiation microspheres and chemotherapy (chemo-radiotherapy) improved progression-free survival in the liver by around eight months among metastatic bowel cancer patients. The SIRFLOX study – the world’s largest study of its kind involving 530 metastatic bowel cancer patients…

Read More

Protect against pneumococcal pneumonia – May 24, 2015

“Pneumococcal pneumonia is a severe lung infection caused by the bacterium Streptococcus pneumoniae, responsible for a large proportion of pneumonia cases among those aged 65 years and above” – A/Prof Lucy Morgan.  According to Lung Foundation Australia’s ‘Lungs4Life’ research released this week, fewer than one-in-seven Australians (14 per cent) aged 18 to 74 who have…

Read More